Quality by design (QbD) approach to formulate in situ gelling system for nose to brain delivery of Fluoxetine hydrochloride: Ex-vivo and In-vivo study
Ars Pharmaceutica (Internet) · 20.09.2017 · 58 (3) · 107-114
DOI: 10.30827/ars.v58i3.6528 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ars Pharmaceutica (Internet), online erschienen am 20.09.2017. Verfasst von Inayat Bashir Pathan und 2 weiteren Autor:innen. Die Arbeit wurde bisher 23-mal zitiert (Crossref).
Abstract (Originalsprache)
Objective
The purpose of the present study is to develop an ion sensitive in situ nasal gel of Fluoxetine hydrochloride for brain delivery. A 32 factorial design was used to investigate effect of independent variable on dependent variables.
Methods
Formulations were evaluated for gelation study, viscosity, gel strength, mucoadhesion strength, drug content, ex-vivo drug permeation, in vivo pharmacodynamic and stability study.
Results
The results revealed that as the concentration of gellan gum and HPMC were increased, there was increase in viscosity and mucoadhesive strength and decrease in percent release. The optimized formulation F4 showed highest drug release 94.24 %. In locomotor activity and forced swim test study, the in situ gel treated rats showed significant responses as compared to control group. Histopathological examinations showed no evidence of nasal mucosal damage. The in situ nasal gel was stable after 3 months.
Conclusion
It was concluded that, the in situ nasal formulations of Fluoxetine hydrochloride which enhanced nasal absorption and patient compliance for the treatment of depression.
Zitieren
APA
Pathan, I. B., Mene, H., & Bairagi, S. (2017). Quality by design (QbD) approach to formulate in situ gelling system for nose to brain delivery of Fluoxetine hydrochloride: Ex-vivo and In-vivo study. Ars Pharmaceutica (Internet), 58(3), 107-114. https://doi.org/10.30827/ars.v58i3.6528
Vancouver
Pathan IB, Mene H, Bairagi S. Quality by design (QbD) approach to formulate in situ gelling system for nose to brain delivery of Fluoxetine hydrochloride: Ex-vivo and In-vivo study. Ars Pharmaceutica (Internet). 2017;58(3):107-114. doi:10.30827/ars.v58i3.6528
BibTeX
@article{Pathan2017,
author = {Pathan, Inayat Bashir and Mene, Harshal and Bairagi, Shripad},
title = {Quality by design (QbD) approach to formulate in situ gelling system for nose to brain delivery of Fluoxetine hydrochloride: Ex-vivo and In-vivo study},
journal = {Ars Pharmaceutica (Internet)},
year = {2017},
volume = {58},
number = {3},
pages = {107--114},
doi = {10.30827/ars.v58i3.6528}
}
EUVIMED